| 史志琦,赵丽丽,朱艺宸,等.表皮生长因子受体酪氨酸激酶抑制剂耐药后非小细胞肺癌免疫治疗的研究进展[J].肿瘤学杂志,2024,30(12):991-998. |
| 表皮生长因子受体酪氨酸激酶抑制剂耐药后非小细胞肺癌免疫治疗的研究进展 |
| Research Progress on Immunotherapy for Non-Small Cell Lung Cancer Resistant to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor |
| 投稿时间：2024-10-07 |
| DOI：10.11735/j.issn.1671-170X.2024.12.B003 |
|
 |
| 中文关键词: 非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 表皮生长因子受体 免疫疗法 耐药 |
| 英文关键词:non-small cell lung cancer epidermal growth factor receptor-tyrosine kinase inhibitor epidermal growth factor receptor immunotherapy resistance |
| 基金项目:山东省中医药科技重点项目（2012Z31）；2022—2024年青岛市临床重点专科攀登高峰学科计划（2022-10） |
|
| 摘要点击次数: 150 |
| 全文下载次数: 30 |
| 中文摘要: |
| 摘 要：表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI）是表皮生长因子受体（epidermal growth factor receptor，EGFR）突变的晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者的标准一线治疗方案，EGFR-TKI耐药严重影响患者预后，EGFR-TKI耐药机制的探讨及后续治疗是当前研究的难点和重点。近年来，免疫检查点抑制剂在EGFR-TKI耐药晚期NSCLC的治疗中展现出显著优势。全文就EGFR-TKI耐药NSCLC的免疫相关机制、免疫单药、免疫联合靶向、化疗、抗血管生成、双抗等治疗现状进行分析，并就PD-L1表达、肿瘤突变负荷（tumor mutation burden，TMB）、EGFR突变类型及代谢产物等指标预测选择EGFR-TKI耐药后的优势人群进行阐述，以期为EGFR-TKI耐药NSCLC患者治疗研究及临床提供参考。 |
| 英文摘要: |
| Abstract： Epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI) is the standard first-line treatment option for patients with advanced non-small cell lung cancer(NSCLC) with epidermal growth factor receptor (EGFR) mutations. EGFR-TKI resistance seriously affects the prognosis of patients， and the exploration of the mechanism of EGFR-TKI resistance and the subsequent treatment are the difficulties and focuses of the current research. In recent years， immune checkpoint inhibitors have demonstrated significant advantages in the treatment of EGFR-TKI-resistant advanced NSCLC. This paper analyzes the immune related mechanisms， immune monotherapy， immune combination targeting， chemotherapy， anti angiogenesis， dual antibody and other treatment status of EGFR-TKI resistant NSCLC. It also elaborates on the prediction of PD-L1 expression， tumor mutation burden (TMB)， EGFR mutation type and metabolic products to select the dominant population after EGFR-TKI resistance， in order to provide reference for the treatment research and clinical practice of EGFR-TKI resistant NSCLC patients. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |